NO20001515L - Vitronectin receptor antagonist - Google Patents

Vitronectin receptor antagonist

Info

Publication number
NO20001515L
NO20001515L NO20001515A NO20001515A NO20001515L NO 20001515 L NO20001515 L NO 20001515L NO 20001515 A NO20001515 A NO 20001515A NO 20001515 A NO20001515 A NO 20001515A NO 20001515 L NO20001515 L NO 20001515L
Authority
NO
Norway
Prior art keywords
receptor antagonist
vitronectin receptor
vitronectin
osteoporosis
useful
Prior art date
Application number
NO20001515A
Other languages
Norwegian (no)
Other versions
NO20001515D0 (en
Inventor
William E Bondinelli
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20001515L publication Critical patent/NO20001515L/en
Publication of NO20001515D0 publication Critical patent/NO20001515D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En forbindelse med formel (I) er beskrevet som er en vitronektin-reseptorantagonist og er nyttige ved behandling av osteoporose: eller et farmasøytisk godtagbart salt derav.A compound of formula (I) is disclosed which is a vitronectin receptor antagonist and useful in the treatment of osteoporosis: or a pharmaceutically acceptable salt thereof.

NO20001515A 1997-09-24 2000-03-23 Vitronectin receptor antagonist NO20001515D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5986797P 1997-09-24 1997-09-24
PCT/US1998/019987 WO1999015178A1 (en) 1997-09-24 1998-09-24 Vitronectin receptor antagonist

Publications (2)

Publication Number Publication Date
NO20001515L true NO20001515L (en) 2000-03-23
NO20001515D0 NO20001515D0 (en) 2000-03-23

Family

ID=22025805

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001515A NO20001515D0 (en) 1997-09-24 2000-03-23 Vitronectin receptor antagonist

Country Status (13)

Country Link
EP (1) EP1023073A1 (en)
JP (1) JP2002500162A (en)
KR (1) KR20010024249A (en)
CN (1) CN1271284A (en)
AU (1) AU9578798A (en)
BR (1) BR9813214A (en)
CA (1) CA2304000A1 (en)
HU (1) HUP0003931A2 (en)
IL (1) IL135188A0 (en)
NO (1) NO20001515D0 (en)
PL (1) PL339414A1 (en)
TR (1) TR200000786T2 (en)
WO (1) WO1999015178A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1150965A4 (en) 1999-02-03 2002-05-15 Merck & Co Inc Benzazepine derivatives as alpha-v integrin receptor antagonists
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
EP1381384B1 (en) 2001-04-24 2011-05-25 Merck Patent GmbH COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha
WO2003059251A2 (en) 2001-10-22 2003-07-24 The Scripps Research Institute Antibody targeting compounds
EP1628949A4 (en) 2003-04-04 2008-07-02 Smithkline Beecham Corp Process and intermediates for preparing benzazepines
CA2554644C (en) 2004-02-02 2015-06-16 Pioneer Hi-Bred International, Inc. Ap2 domain transcription factor odp2 (ovule development protein 2) and methods of use
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EP2335733B1 (en) 2006-01-18 2014-08-06 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
CN101588812A (en) 2007-01-18 2009-11-25 默克专利有限公司 Specific therapy and medicament using integrin ligands for treating cancer
CA2705916C (en) 2007-11-16 2016-01-05 Ube Industries, Ltd. Benzazepinone compound
WO2009111679A2 (en) * 2008-03-06 2009-09-11 Smithkline Beecham Corporation Process
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
US20120095215A1 (en) 2009-03-30 2012-04-19 Ube Industries, Ltd. Medical composition for treatment or prophylaxis of eye diseases
WO2010136168A2 (en) 2009-05-25 2010-12-02 Merck Patent Gmbh Continuous administration of integrin ligands for treating cancer
AU2010339404B2 (en) 2009-12-30 2016-01-28 Pioneer Hi-Bred International, Inc. Methods and compositions for the introduction and regulated expression of genes in plants
AU2010339481B2 (en) 2009-12-30 2016-02-04 Pioneer Hi-Bred International, Inc. Methods and compositions for targeted polynucleotide modification
EP3148587B1 (en) 2014-05-30 2021-02-24 Pfizer Inc Carbonitrile derivatives as selective androgen receptor modulators
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60311C2 (en) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Vitronectin receptor antagonists

Also Published As

Publication number Publication date
HUP0003931A2 (en) 2001-10-28
JP2002500162A (en) 2002-01-08
WO1999015178A1 (en) 1999-04-01
PL339414A1 (en) 2000-12-18
CN1271284A (en) 2000-10-25
KR20010024249A (en) 2001-03-26
EP1023073A1 (en) 2000-08-02
NO20001515D0 (en) 2000-03-23
CA2304000A1 (en) 1999-04-01
AU9578798A (en) 1999-04-12
IL135188A0 (en) 2001-05-20
TR200000786T2 (en) 2000-08-21
BR9813214A (en) 2000-08-29

Similar Documents

Publication Publication Date Title
NO20001515L (en) Vitronectin receptor antagonist
NO20001514L (en) Vitronectin receptor antagonist
NO983002L (en) Vitronectin receptor antagonists
NO983003L (en) Vitronectin receptor antagonists
NO20025821L (en) 2-aminocarbonyl-9H-purine
IL133623A0 (en) Antithrombotic agents
EP0999834A4 (en) Antithrombotic agents
DK0896533T3 (en) Pentafluorobenzene sulfonamides and analogues
GB9514473D0 (en) Chemical compounds
FI964815A0 (en) Piperazine derivatives as 5-HT1A antagonists
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
SG44989A1 (en) Crystalline hydrochloride of (R)-(-)-2-{N-[4-(1,1-dioxid-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman
DE60121461D1 (en) CONDENSED PYRIDOINDOL DERIVATIVES
BR9812340A (en) Vitronectin receptor antagonists
NO975975L (en) Vitronectin receptor antagonists, preparation and use thereof
ATE240339T1 (en) NUCLEOTIDE ANALOGUES
ATE359793T1 (en) 2-METHYL-THIENO-BENZODIAZEPINE FORMULATION
AP1534A (en) Vitronectin receptor antagonists.
WO1998031704A3 (en) Tachykinin antagonists
WO2001017959A3 (en) Vitronectin receptor antagonists
NO20004545L (en) Process for the preparation of (R) - <alpha> - (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-piperidinemethanol
WO2000007544A3 (en) Vitronectin receptor antagonists
NO306673B1 (en) Intermediate for the preparation of pharmaceutically active compound
NO953480L (en) Use and Method of Treatment Using Carbazolyl (4) Oxypropylamine Compounds for Inhibition of Smooth Muscle Cell Propagation
IT1303687B1 (en) USE OF GAMMA HYDROXYBUTIRRIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALT FOR ISCHEMIA TREATMENT

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application